Yet, under these unfavorable circumstances and although the study was not powered to detect treatment by MAF status interactions, a clear trend is detected comparing the OS outcomes of MAF (+) vs (–) patients with a P interaction of .06.
← all excerpts
<i>MAF</i> Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice.
1
—
—